SCHEMBL10028045

SCHEMBL10028045

CNC(=O)c1ccc(-c2ccccc2Cl)o1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.69
SMN1; SMN2 Q16637 6/20 0.69
MAPT P10636 5/20 0.69
MEN1 O00255 5/20 0.69
KMT2A Q03164 5/20 0.69
LMNA P02545 5/20 0.69
CASP3 P42574 4/20 0.69
SENP7 Q9BQF6 4/20 0.69
MAPK1 P28482 3/20 0.69
RECQL P46063 1/20 0.69
ALDH1A1 P00352 8/20 0.67
NPSR1 Q6W5P4 2/20 0.67
TDP1 Q9NUW8 1/20 0.67
NPC1 O15118 4/20 0.64
SENP6 Q9GZR1 2/20 0.64
HPGD P15428 5/20 0.63
HTT P42858 3/20 0.60
ERCC5 P28715 1/20 0.59
FEN1 P39748 1/20 0.59
KDM4E B2RXH2 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21067946 0.84 RAB9A (0.69) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4942886 0.83 ALDH1A1 (0.69) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4036255 0.82 ALDH1A1 (0.73) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4987351 0.80 ALDH1A1 (1.00) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL28269605 0.80 ALDH1A1 (0.75) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL29352723 0.80 ALDH1A1 (1.00) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL27706946 0.80 ALDH1A1 (0.72) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4942987 0.80 RAB9A (0.63) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL12050743 0.77 S1PR4 (0.63) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL11634779 0.76 ERCC5 (0.68) RAB9ASMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010259-A1 Methods of Treating an Overweight or Obese Subject ZAFGEN, INC. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010259-A1 Methods of Treating an Overweight or Obese Subject METAP2, METAP1, ACER2 RAB9A 3416/4885SMN1; SMN2 1171/4885MAPT 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.